{
    "clinical_study": {
        "@rank": "19828", 
        "arm_group": [
            {
                "arm_group_label": "Embozene\u00ae Microspheres", 
                "arm_group_type": "Experimental", 
                "description": "Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink."
            }, 
            {
                "arm_group_label": "Embosphere\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, prospective, multi-center study of 225 female subjects age 30-50 years\n      with symptoms from uterine fibroids.  All subjects will be followed for a total of\n      thirty-six (36) months following uterine fibroid embolization."
        }, 
        "brief_title": "Embozene Microspheres for Uterine Fibroid Embolization (UFE)", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Uterine Fibroids", 
        "condition_browse": {
            "mesh_term": [
                "Leiomyoma", 
                "Myofibroma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is able to provide informed consent and must sign the Institutional Review\n             Board approved Informed Consent Form.\n\n          -  Pre-menopausal women age 30-50 years at time of enrollment\n\n          -  Have been selected forUterine Fibroid Embolization (UFE) prior to entry to the study.\n\n        Exclusion Criteria:\n\n          -  Patient has a history of pelvic malignancy\n\n          -  Patient has an abnormal Pap smear within 12 months of the planned Uterine Fibroid\n             Embolization procedure\n\n          -  Patient with coexisting condition that might explain abnormal bleeding (including\n             endometrial hyperplasia and adenomyosis) or pelvic pain (including endometriosis and\n             ovarian cysts).\n\n          -  Is at substantial risk for the need of organ transplantation, such as renal\n             insufficiency.\n\n          -  Patient has evidence of current or recent pelvic inflammatory disease or uterine\n             infection.\n\n          -  Patient with a severe contrast allergy or renal insufficiency that would represent a\n             contradiction to the administration of iodine-based contrast agents.\n\n          -  Patients unable to comply with the follow-up requirements of the study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675011", 
            "org_study_id": "2010-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Embozene\u00ae Microspheres", 
                "intervention_name": "Embozene\u00ae Microspheres", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Embosphere\u00ae", 
                "intervention_name": "Embosphere\u00ae", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Albany Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Hyde Park", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "North Shore LIJ Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization Compared to Embosphere for Symptomatic Relief From Uterine Fibroids", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary effectiveness endpoint for this clinical trial is the proportion of subjects who have success, defined as 50% menstrual blood loss (MBL) reduction or less than 80 ml of MBL per cycle, evaluated by the Alkaline Hematin (AH) method, at 12 months.", 
            "measure": "Primary Endpoint", 
            "safety_issue": "Yes", 
            "time_frame": "12 Months post study procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675011"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "CeloNova BioSciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CeloNova BioSciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014", 
        "why_stopped": "Inadequate enrollment"
    }
}